Hosted in the Exhibition Area

Seth Painter, Director, Strategic Partnerships, Ostro
Brad Aufderheide, SVP, Oncology & Rare Disease Strategy, Klick

• What is the state of the patient experience for rare disease patients and pharma?
• How is empathy being incorporated to improve the rare disease patient experience?
• Share an example of how a patient experience has affected your product / market / therapy area
• Share an example of how data and technology play a role when considering the rare disease patient experience
• How do we push further to include patient experience and patient voice into all aspects of pharma?

Wendy Erler, VP, Global Head Patient Experience: Patient Centricity, Insights and Advocacy, Alexion
Marshall Thompson, Sr. Manager, Digital Marketing, US Rare Disease, Alnylam Pharmaceuticals
Gemma Mayman, VP, Specialty Care Patient Solutions and Engagement Lead, Pfizer

Moderated by:  Megan Nolan, Founder & Editor-in-Chief, Rare Parenting

We know that a better experience is possible. Look at all we’ve learned from the consumerization of ordering movies, shopping for prescription glasses, or hailing a ride to the airport. It seems that every other segment of society but healthcare has figured out that the secret to a successful engagement is to get you the information, goods, or services you’re looking for with the least amount of scrolling and clicking. So why not rare disease?

Ahmed Elsayyad, President and Co-Founder, Ostro

Bonnie Perkins, Senior Director, Patient Engagement, Rare Disease, Alexion

This panel will discuss the role of advocacy groups in the overall commercial model and customer experience.

• Patients are obviously at the forefront of advocacy groups, but what is the role of advocacy as it pertains to HCP?
• Examples of advocacy partnerships and how they contribute to optimal CX
• Are there any areas where advocacy should not be involved?
• Who is further along in leveraging technology—pharma or advocacy?
• What are some ways that technology is being leveraged collaboratively to optimize CX in rare disease?

Aprill Lane, US Advocacy Lead, Rare Disease, UCB
Deb Katz, Patient Advocacy Director, SpringWorks Therapeutics

• Learn how marketing content impacts the outcome and affects the perception of HCPs and what you can do to change that
• Elevate the content presented to HCPs to build invested relationships that are valuable for them and their patients
• Collect feedback from HCPs and your sales peers on what is working and what needs to change to make your product stand out

Jason Plant, Rare Disease Commercial Leader, Director, National Accounts, Ardelyx

Jennifer Anderson, Director, HAE Customer Innovation and Operations, Takeda
Elaine Kang, US Marketing Director, SpringWorks Therapeutics

Moderated by: Elizabeth Beringer, President, Spring & Bond

Noah Bryant, Social Media and Digital Marketing, US, Novocure

• How are pharma marketers leveraging data and analytics to improve patient experiences in the rare disease space?
• How can data-driven insights be utilized to enhance engagement with HCPs?
• What metrics are most valuable for rare disease patient and HCP marketing initiatives?
• How is AI being utilized in rare disease patient and HCP marketing efforts?
• What are the biggest challenges with data implementation and common pitfalls to avoid?

Nathan Cheng, Commercial/Medical Affairs Data Business Partner, Alnylam
Shannon Nolte, Sr. Manager, Rare Disease Customer Data and Insights, Biogen
Joseph Leo, Sr. Manager, Data Strategy - Rare Disease Data Partner, Novo Nordisk

Moderated by: Paul Reuscher, VP, Product Innovation, Forian